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Abstract
Hepatic fibrosis in patients with non-alcoholic fatty liver disease is
associated with progression of the disease. In the present study, we
analyzed the discriminative ability of serum laminin, type IV collagen
and hyaluronan levels to predict the presence of fibrosis in these
patients. In this preliminary report, we studied 30 overweight patients
divided into two groups according to the absence (group I, N = 19) or
presence (group II, N = 11) of fibrosis in a liver biopsy. Triglycerides,
aspartate aminotransferase, alanine aminotransferase, γ-glutamyl-
transpeptidade, hyaluronan (noncompetitive fluoroassay), type IV
collagen, and laminin (ELISA) were determined. Group II presented
significantly higher mean laminin, hyaluronan, type IV collagen, and
aspartate aminotransferase values, which were due to the correlation
between these parameters and the stage of fibrosis in the biopsy
(Spearman’s correlation coefficient, rS = 0.65, 0.62, 0.53, and 0.49,
respectively). Analysis of the ROC curve showed that laminin values
>282 ng/ml were those with the best diagnostic performance, with
87% accuracy. Association of laminin with type IV collagen showed
improvement in the positive predictive value (100%), but with reduc-
tion in diagnostic sensitivity (64%). When compared with the criteria
of Ratziu et al. [Gastroenterology (2000) 118: 1117-1123] for the
diagnosis of septal fibrosis, laminin values presented a better diagnos-
tic accuracy (83 vs 70%). Determination of extracellular matrix com-
ponents in serum, especially of laminin, may identify patients with
non-alcoholic fatty liver disease and fibrosis and these components
may be used as indicators for liver biopsy in these patients.
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Introduction
Non-alcoholic fatty liver disease (NAFLD)
affects approximately 20% of the general
population (1,2). Most of these patients pres-
ent steatosis alone or associated only with an
inflammatory infiltrate, without degenera-
tive or fibrotic alterations. The follow-up of
these patients shows that the disease is stable
(3,4). However, in about 2-3% of the popula-
tion steatosis will be accompanied by bal-
looning degeneration, Mallory’s hyaline bod-
ies and fibrosis, characterizing non-alcoholic
steatohepatitis (NASH) which may progress
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to cirrhosis and liver failure (4-6).
Differentiation between these NAFLD
forms can be safely performed only by liver
biopsy (4,7-9). However, due to the high
prevalence of the disease, it would be neces-
sary to find noninvasive parameters which
would allow the selection of patients at a
higher risk of developing cirrhosis to be
submitted to a biopsy, despite the slight risk
of mortality and morbidity involved.
The presence of fibrosis in the biopsy is
accompanied by progression of the disease to
cirrhosis and liver failure in 15 to 26% of cases
(3-6), thus constituting a criterion of NAFLD
severity. On the other hand, extracellular ma-
trix components, especially type III and IV
collagens (COL-IV), laminin (LM) and hyalu-
ronic acid (HA), have been used as indirect
fibrogenesis markers in many chronic liver
diseases, such as hemochromatosis, viral hepa-
titis and alcoholic liver disease (10-13).
In the present study, we assessed the
discriminative ability of serum LM and COL-
IV to predict the presence of fibrosis in
NAFLD in patients with compensated dis-
ease, without clinical or ultrasound signs of
cirrhosis or portal hypertension.
Patients and Methods
Thirty patients with body mass index
(BMI) >25, with an ultrasound diagnosis of
liver steatosis and with a persistent increase
of at least 1.5 times the upper limit of nor-
mality of aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and/or γ-
glutamyltranspeptidase (γ-GT) levels for a
minimum period of three months were stud-
ied. All patients were submitted to a percuta-
neous liver biopsy.
Patients ingesting more than 20 g alcohol
per day, with decompensated non-insulin-
dependent diabetes mellitus (NIDDM), tak-
ing hepatotoxic drugs, with systemic dis-
eases or infections, those presenting hepati-
tis B or C virus or other concomitant liver
disease were excluded. Patients with clinical
and/or ultrasound signs of liver failure and/
or portal hypertension were also excluded.
Serum COL-IV and LM concentrations
were determined by ELISA with mouse
monoclonal antibodies against human LM
and COL-IV using commercial Fuji Chemi-
cal Ind. (Takaoka, Tokyo, Japan) kits.
HA determinations were performed us-
ing a noncompetitive fluorescence-based
assay with specific binding proteins from
bovine cartilage which were later used in
solid phase on ELISA plates and with biotin-
ylated probes (14,15).
Biopsy fragments were stained with he-
matoxylin-eosin, Masson’s trichrome, Prus-
sian blue (Perls’ test), and reticulum impreg-
nation with silver (Gomori).
NAFLD grading of liver tissue samples
was performed according to Lee (16), Brunt
et al. (17), and Dixon et al. (18). Liver steato-
sis was classified according to the percent-
age of fatty vacuole-containing hepatocytes:
grade 0 (absent), grade 1 (<5% of the hepa-
tocytes), grade 2 (5-25% of the hepatocytes),
grade 3 (25-75% of the hepatocytes), grade 4
(>75% of the hepatocytes). Lobular inflam-
mation, portal inflammation, hepatocyte bal-
looning, and Mallory’s hyaline bodies were
also evaluated. Fibrosis was classified into 0
= absent; stage 1 = perisinusoidal/pericellu-
lar fibrosis in zone 3; stage 2 = perisinusoi-
dal/pericellular fibrosis in zone 3, with focal
or diffuse periportal fibrosis; stage 3 = peri-
sinusoidal/pericellular fibrosis and focal por-
tal fibrosis with focal or diffuse bridging
fibrosis; stage 4 = cirrhosis. Patients with
cirrhosis and portal fibrous expansion with
emission of septa of any intensity were clas-
sified as patients with septal fibrosis.
NAFLD was classified on the basis of
histological data using the classification of
Matteoni et al. (4): type 1 (isolated liver
steatosis); type 2 (liver steatosis and lobular
inflammation); type 3 (presence of hepato-
cyte ballooning); type 4 (presence of
Mallory’s hyaline bodies and/or fibrosis).
After evaluation of the histological pa-
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rameters, the patients included in the study
were divided into 2 groups: group I (patients
with type 1, 2 and 3 NAFLD) and group II
(patients with type 4 NAFLD, with fibrosis).
BMI, age, ALT, and triglyceride concen-
trations (BAAT criteria) were considered
for the evaluation of parameters indicating
fibrosis in overweight patients according to
the criteria proposed by Ratziu et al. (19).
The Mann-Whitney test and the Spear-
man nonparametric correlation coefficient
were used for statistical analysis. The dis-
criminative power of each variable was as-
sessed on the basis of positive predicting
value, negative predicting value and accu-
racy, with determination of the cut-off of the
area under the ROC curve. The level of
significance was set at 5% in all analyses
(20,21).
Results
A total of 186 patients were originally
evaluated, 156 of whom were excluded for
various reasons, the main cause being the
ingestion of more than 20 g/day alcohol. Re-
fusal to submit to a biopsy, use of hepatotoxic
drugs, and signs of advanced hepatopathy were
other frequent causes of exclusion.
Of the 30 patients included, 18 were
males. Mean age was 44.9 years. All patients
presented BMI >25, with a mean of 31. Eight
patients (26.7%) presented hepatomegaly
with no signs suggestive of hepatocellular
failure.
Besides obesity, 7 patients (23.3%) pre-
sented NIDDM and dyslipidemia, without
identification of any other risk factor for
NAFLD development.
Based on the histological data obtained,
6 patients were classified as type 1, 10 as
type 2, 3 as type 3, and 11 as type 4 NAFLD
according to the criteria proposed by Matteoni
et al. (4).
Upon histological analysis all patients
presented steatosis, with 43.3% of the cases
being grades 1 and 2. No correlation be-
Table 1. Biochemical (serum) and demographic parameters of patients with non-
alcoholic fatty liver disease with (group I) and without (group II) fibrosis.
Parameter Group I (N = 19) Group II (N = 11)
Gender (male/female) 11/8 7/4
Age (years) 41.6 ± 2.90 50.5 ± 4.10
BMI 31.1 ± 1.00 31 ± 2.40
ALT (IU/l) 60.6 ± 11.5 105.8 ± 34.3
AST (IU/l) 36.4 ± 5.90 47.6 ± 3.10*
AST/ALT ratio 0.7 ± 0.1 0.7 ± 0.1
γ-GT (IU/l) 84.9 ± 12.5 118.4 ± 30.4
Type IV collagen (ng/ml) 116.7 ± 4.6 149.3 ± 12*
Laminin (ng/ml) 244.7 ± 11.9 381.4 ± 38.9*
Hyaluronan (ng/ml) 25.6 ± 7.0 73.5 ± 23.5*
Data are reported as means ± SEM. BMI = body mass index; ALT = alanine
aminotransferase; AST = aspartate aminotransferase; γ-GT = γ-glutamyltranspepti-
dase.
*P < 0.05 compared to group I (Mann-Whitney test).
tween steatosis grade and severity of NAFLD
classification was observed. Fibrosis was
found in 11 (36.7%) of the 30 patients evalu-
ated.
The groups, separated according to the
presence or absence of fibrosis, did not dif-
fer regarding age, gender or the presence of
signs and symptoms on the occasion of diag-
nosis. They also did not differ regarding γ-
GT, ALT levels and AST/ALT ratio. Mean
AST levels as well as serum COL-IV, LM
and HA levels were significantly higher in
group II (Table 1).
Serum LM levels correlated significantly
with fibrosis grade (P = 0.65), Mallory’s
bodies (P = 0.51) and lobular inflammation
(P = 0.50), the same being observed for HA
(P = 0.62), COL-IV (0.53), and AST (0.49)
levels. Figure 1 shows the correlation be-
Figure 1. Correlation between
serum laminin concentrations
and grade of fibrosis in liver bi-
opsies. Correlation between
these parameters was calcu-
lated by the Spearman non-
parametric correlation coeffi-
cient (rS).
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tween serum LM values and grade of fibrosis
in liver biopsy.
Once the discriminative values of each
parameter were evaluated, we observed that,
based on the ROC curve, the best diagnostic
accuracy in the identification of patients with
NAFLD and fibrosis was obtained with se-
rum LM levels, followed by AST and HA
values. Association of serum LM values with
HA, COL-IV or AST determinations showed
improvement in the positive predictive value
(specially for the combination of LM with
COL-IV values), but with an important re-
duction in diagnostic sensitivity (Table 2).
Serum LM values were then compared
with BAAT criteria (22) considering the di-
agnosis of septal fibrosis (stages 2 to 4). In
such situation, LM determination presented
a better diagnostic performance than the
BAAT score (Table 3).
Discussion
NAFLD is currently the most prevalent
liver disease worldwide. Since it may be
associated with different risk factors, we
included in this study only overweight indi-
viduals who did not present significant varia-
tion in body weight during the last three
months. These patients presented a high
NAFLD prevalence (23-25), often associ-
ated with the presence of fibrosis (7).
With the potential progress of NAFLD to
cirrhosis, an adequate evaluation of these
patients is required in order to define the
prognosis of the disease. Retrospective stud-
ies have indicated that, if steatosis associ-
ated or not with an inflammatory infiltrate is
detected in a biopsy, no progression of the
disease is observed even during follow-up of
the patients for a long period of time (3,4).
On the other hand, in patients with associ-
ated ballooning degeneration and/or Mallo-
ry’s bodies with or without fibrosis, the de-
velopment of cirrhosis can be observed in up
to 30% of cases (4,26,27). In addition, the
presence of liver fibrosis, even in its initial
form, seems to be a good marker for the
evolution of the disease, as observed by
Matteoni et al. (4).
Therefore, based on a liver biopsy, pa-
tients with liver fibrosis (group II) were sepa-
rated from the other NAFLD patients (group
I) in the expectation that this increase in
fibrogenic activity could be detected by se-
rum determination of extracellular matrix
components.
No differences were observed between
these groups regarding clinical or demo-
graphic characteristics (gender, age, BMI,
present signs and symptoms), or ALT and γ-
GT levels and the AST/ALT ratio. Several
studies have shown that serum ALT and γ-
GT and the AST/ALT ratio may represent
indicators of advanced liver disease and fi-
brosis (3,8,19,26,28). In particular, an AST/
ALT ratio >1 would be observed in patients
with a more advanced grade of liver fibrosis,
such as cirrhosis and septal fibrosis (4,7). In
our patients, the AST/ALT ratio was less
than 1 in both groups, certainly reflecting the
selection criterion by which patients with
signs of liver failure and with manifest portal
hypertension were excluded from this study.
However, AST levels were significantly
higher in group II patients, as also reported
by others (4,7,29). Such difference seems to
be due to the significant correlation observed
between this parameter and the grade of
Table 2. Discriminative serum concentrations of extracellular matrix components and
of aspartate aminotransferase alone or associated with laminin values for the identifi-
cation of fibrosis in patients with non-alcoholic fatty liver disease.
SEN SP PPV NPV Accuracy
Laminin (>282 ng/ml) 82 89 82 89 87
Type IV collagen (>145 ng/ml) 64 89 78 81 80
Hyaluronan (>24.6 ng/ml) 82 68 60 87 73
AST (>44 IU/l) 64 79 70 75 73
Laminin + hyaluronan 73 95 89 86 87
Laminin + type IV collagen 64 100 100 83 87
Laminin + AST 55 95 86 78 80
Data are reported as percent. SEN = sensitivity; SP = specificity; PPV = positive
predictive value; NPV = negative predictive value; AST = aspartate aminotrans-
ferase.
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fibrosis in the biopsy. It is believed that AST
clearance by endothelial liver cells is de-
creased in individuals with advanced fibro-
sis, possibly explaining the correlation ob-
served (30).
The extracellular matrix components stud-
ied presented significantly higher values in
patients with liver fibrosis than in those with-
out this histological finding. Among the ex-
tracellular matrix components, we selected
for this study those with the highest correla-
tion with parenchymatous and perisinusoidal
fibrosis as it occurs in NAFLD (31-33). LM
is the largest protein of the basement mem-
brane and in chronic liver diseases it is pro-
gressively deposited along Disse’s space ac-
companying sinusoid capillarization (34,35).
In these patients, its serum values have been
related to the degree of portal hypertension
(13,36,37) and, together with HA determi-
nation, to the diagnosis of fibrosis (31). COL-
IV is the main collagen component of the
basement membrane, being co-distributed
with LM in the perisinusoidal space (32,35).
Studies on patients with chronic liver dis-
ease have demonstrated a relationship be-
tween serum COL-IV values and severity of
liver fibrosis (22,32). HA is a non-sulfated
glycosaminoglycan synthesized in the liver
by stellate cells. Its serum concentration sig-
nificantly increases in chronic diseases of
the liver of different etiologies, due not only
to a greater hepatic production but also to a
decrease in its degradation by endothelial
liver cells (33,38). In these patients, espe-
cially those with disease of viral and alco-
holic etiology, increased levels of this gly-
cosaminoglycan have been detected and were
shown to be related to the degree of fibrosis
in liver tissue (38,39).
We confirmed this association between
serum concentration of these extracellular
matrix components and the degree of fibro-
sis in patients with NAFLD. In addition, we
also observed a significant correlation of
such parameters with the presence of
Mallory’s bodies which are associated with
a higher fibrogenic activity of the disease (4,
18). Type IV collagen, instead, was the only
parameter correlated with hepatocyte bal-
looning and steatosis grade, suggesting a
relationship between this basement mem-
brane protein and lipid metabolism. How-
ever, the mechanism of this interaction is
still unknown.
In attempts to obtain a noninvasive diag-
nosis of fibrosis, several parameters have
been proposed (7,18,19). Since our study
only included overweight patients, it was
closer to that by Ratziu et al. (19) who pro-
posed an index of fibrosis predictors based
on BAAT criteria. Comparing the discrimi-
native ability of blood LM concentrations
with these BAAT criteria, it can be observed
that LM values presented a better diagnostic
performance for the diagnosis of septal fi-
brosis. It should be emphasized that the val-
ues observed here were similar to those de-
scribed in the original paper by the cited
authors.
It is important to note that the patients in
the present study did not present any clinical
or ultrasound sign of chronic liver disease,
exactly because our intention was to assess
patients who did not present the stigmata of
liver failure or indirect signs of liver cirrho-
sis, in need of a biopsy to define the diagno-
sis and prognosis of the disease. Thus, in this
type of patient, the finding of high LM val-
ues would be associated with liver fibrosis in
82% of the cases and would present a false-
Table 3. Discriminative values of laminin and of
BAAT criteria (body mass index, age, alanine ami-
notransferase and triglyceride concentrations) for
the diagnosis of septal fibrosis and cirrhosis in over-
weight patients with non-alcoholic fatty liver dis-
ease.
Parameter PPV NPV Accuracy
Laminin 64 95 83
BAAT 47 93 70
Data are reported as percent. PPV = positive pre-
dictive value; NPV = negative predictive value.
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negative result in about 10% of the cases.
Therefore, LM determination could be used
for the screening of patients to be submitted
to a liver biopsy, since it presents a better
performance than the criteria currently used
to indicate a biopsy for these patients (7,19).
On the other hand, the good performance
observed for serum AST levels should be
emphasized. Differentiation of advanced
NAFLD forms according to AST values has
also been reported by other authors (4,18),
who, however, did not evaluate the discrimi-
native ability of this determination. Since the
observed cut-off value represents a 1.5-fold
increase in the upper limit of normality and
since it is an easily obtained biochemical
parameter, it is especially attractive for the
selection of patients for biopsy.
The results of the present study show the
important contribution made by the determi-
nation of extracellular matrix components,
especially LM, and also of AST levels, to the
selection of patients with NAFLD for a liver
biopsy, in order to identify patients with the
progressive forms of the disease. Studies
involving a larger number of patients and
repeated determinations of these parameters
should be performed for a better evaluation
of their prognostic value in NAFLD.
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